Back to Search Start Over

Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies.

Authors :
van den Bijgaart RJ
Eikelenboom DC
Hoogenboom M
Fütterer JJ
den Brok MH
Adema GJ
Source :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2017 Feb; Vol. 66 (2), pp. 247-258. Date of Electronic Publication: 2016 Sep 01.
Publication Year :
2017

Abstract

Tumor ablation technologies, such as radiofrequency-, cryo- or high-intensity focused ultrasound (HIFU) ablation will destroy tumor tissue in a minimally invasive manner. Ablation generates large volumes of tumor debris in situ, releasing multiple bio-molecules like tumor antigens and damage-associated molecular patterns. To initiate an adaptive antitumor immune response, antigen-presenting cells need to take up tumor antigens and, following activation, present them to immune effector cells. The impact of the type of tumor ablation on the precise nature, availability and suitability of the tumor debris for immune response induction, however, is poorly understood. In this review, we focus on immune effects after HIFU-mediated ablation and compare these to findings using other ablation technologies. HIFU can be used both for thermal and mechanical destruction of tissue, inducing coagulative necrosis or subcellular fragmentation, respectively. Preclinical and clinical results of HIFU tumor ablation show increased infiltration and activation of CD4 <superscript>+</superscript> and CD8 <superscript>+</superscript> T cells. As previously observed for other types of tumor ablation technologies, however, this ablation-induced enhanced infiltration alone appears insufficient to generate consistent protective antitumor immunity. Therapies combining ablation with immune stimulation are therefore expected to be key to boost HIFU-induced immune effects and to achieve systemic, long-lasting, antitumor immunity.<br />Competing Interests: The authors declare that they have no conflict of interest.

Details

Language :
English
ISSN :
1432-0851
Volume :
66
Issue :
2
Database :
MEDLINE
Journal :
Cancer immunology, immunotherapy : CII
Publication Type :
Academic Journal
Accession number :
27585790
Full Text :
https://doi.org/10.1007/s00262-016-1891-9